Epocrates Drug Updates - Editor's Pick

September 25, 2014
Obesity Treatment Contrave Approved

Contrave, an extended-release combination of naltrexone and bupropion hydrochloride was recently approved for the treatment of obesity in conjunction with a reduced-calorie diet and exercise. Contrave is indicated in overweight adults that have a weight-related comorbidity and in obese adults. It carries a Boxed Warning for suicidality and neuropsychiatric reactions related to use of other bupropion products in depression and smoking cessation.

Obesity Treatment Contrave Approved

Recent Updates

September 25, 2014
Keytruda Approved for Metastatic Melanoma
The FDA recently approved Keytruda (pembrolizumab) for melanoma deemed unresectable or progressing after therapy with ipilimumab and/or a BRAF inhibitor. Keytruda is a first-in-class monoclonal antibody directed against the programmed-death 1 (PD-1) receptor on T-cells, thus enhancing the immune response against malignant cells. However, due to its mechanism of action, notable toxicities include immune-mediated reactions that can involve nearly every organ (e.g., pneumonitis, colitis, hepatitis, and nephritis).
Keytruda Approved for Metastatic Melanoma

September 11, 2014
First-Time Generic for Precedex Available
The FDA recently approved dexmedetomidine injection, the first-time generic for Precedex. Precedex is a selective alpha-2 adrenergic agonist approved for ICU sedation and sedation of non-intubated patients prior to and/or during surgical and other procedures.
First-Time Generic for Precedex Available

September 5, 2014
Avastin Approved for Advanced Cervical Cancer
The FDA recently approved a new indication for Avastin (bevacizumab) as treatment for persistent, recurrent, or metastatic cervical cancer when used in combination with paclitaxel and cisplatin or with paclitaxel and topotecan. Avastin is an angiogenesis inhibitor that is also indicated for use in metastatic colorectal cancer, advanced NSCLC, progressive glioblastoma, and metastatic renal cell carcinoma. It carries a Boxed Warning for GI perforation, surgery and wound healing complications, and hemorrhage.
Avastin Approved for Advanced Cervical Cancer

August 28, 2014
Tramadol Declared Schedule IV Drug
The DEA designated the synthetic opioid analgesic tramadol a Schedule IV substance, effective August 18, 2014. Its opioid activity and abuse potential are attributable to both the parent compound and a highly potent active metabolite, M1. Tramadol was previously an uncontrolled substance at the federal level, but its status varied by state, with multiple states already scheduling it as a C-IV drug.
Tramadol Declared Schedule IV Drug

August 28, 2014
Errata
The Delsym Cough + Cold Day Time monograph has been updated to correct the dosing for patients >12 years old to 20 mL PO q4h prn, with a maximum dose of 120 mL/24h. The Delsym Night Time Multi-Symptom monograph has been updated to correct the maximum dose for patients >12 years old to 120 mL/24h.

The Tanzeum half-life was updated for consistency with the product’s labeling. Tanzeum has an elimination half-life of 5 days.

Please update your Epocrates app regularly to ensure that you always have the latest content.
Errata

New Drug Monographs

What is an RSS Feed?

From Wikipedia: "RSS is a simple XML-based system that allows users to subscribe to their favorite websites. Using RSS, webmasters can put their content into a standardized format, which can be viewed and organized through RSS-aware software or automatically conveyed as new content on another website."

email Subscribe by email

Enter your email address:


   Cancel

Delivered by FeedBurner